oncostatin M chimeric antigen receptor T cells

Oncostatin M (OSM) chimeric antigen receptor T cells are a third-generation, ligand-based CAR-T cell therapy developed by researchers at Case Western Reserve University and University Hospitals. Unlike conventional CAR-T therapies that utilize antibody-derived single-chain variable fragments (scFvs), this approach uses the human OSM protein as a targeting ligand. This allows the engineered T cells to bind to the oncostatin M receptor (OSMR) and the leukemia inhibitory factor receptor (LIFR), both of which form signaling heterodimers with glycoprotein 130 (GP130). These receptors are highly expressed on the surface of osteosarcoma and lung adenocarcinoma cells, as well as on cancer-associated fibroblasts (CAFs). By targeting CAFs, OSM CAR-T cells aim to deplete the dense extracellular matrix that typically hinders T-cell infiltration in solid tumors, potentially enhancing therapeutic efficacy in the tumor microenvironment.

Other names

OSM CAR-T cellsoncostatin-M ligand-based CAR T-cells